NCT07163273 - Monthly Alternating NALIRIFOX and GnP in the First-Line Setting | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

June 20, 2025

Primary Completion Date

June 20, 2027

Study Completion Date

June 20, 2027

Conditions

Pancreatic Ductal Adenocarcinoma

Interventions

DRUG

NALIRIFOX

NALIRIFOX consists of 5-FU 2400 mg/m2 over 46 hours, liposomal irinotecan 50 mg/m2, and oxaliplatin 60 mg/m2, which would be given on Day 1 and Day 15

DRUG

Gemcitabine plus nab-Paclitaxel (GnP)

GnP consists of gemcitabine 1000 mg/m2 and nab-paclitaxel 125 mg/m2, given on Days 1, 8, and 15.

Trial Locations (1)

11042

RECRUITING

Zuckerberg Cancer Center, New Hyde Park